94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
REVIEW article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1559581
This article is part of the Research TopicInterdisciplinary Innovations in CAR T Cell Therapy for Autoimmune and Cancer TreatmentView all articles
CAR-NK cell therapy for autoimmune diseases
Provisionally accepted- Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Chimeric antigen receptor natural killer (CAR-NK) cell therapy is revolutionizing the treatment of hematological malignancies. While it cannot be directly compared with pivotal trials of CAR T cells, its toxicity profile appears more favorable. Furthermore, CAR-NK cells are specialized immune effectors capable of recognizing and eliminating targets without human leukocyte antigen (HLA) restriction or prior sensitization. This unique feature prevents graft-versus-host disease, making CAR-NK therapy an ideal treatment. As the field evolves, the transformative potential of CAR NK cells in autoimmune diseases is undeniable, such as systemic lupus erythematosus (SLE), but careful consideration of safety, efficacy, and implementation is essential as this novel therapeutic approach moves forward.
Keywords: CAR-NK cells, Autoimmune Diseases, Immunotherapy, B cells, Allogeneic
Received: 13 Jan 2025; Accepted: 08 Apr 2025.
Copyright: © 2025 Gong, Shengnan Pan and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bangdong Gong, Shanghai Tongji Hospital, School of Medicine, Tongji University, Shanghai, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.